Media and Communications
May 21, 2015
Canadian meeting of vaccine experts identifies gaps, need for multidisciplinary international collaboration in global push for an HIV vaccine
Recent scientific discoveries in HIV illustrate the need for partnerships and collaboration in the effort to develop a safe and effective HIV vaccine. But making alliances work effectively over the long term is a challenge, particularly since an effective HIV vaccine has eluded scientists for over 30 years. With that in mind, 12 Canadian and international experts in HIV discussed collaborations across sectors and borders at the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) Annual Meeting, held in Toronto on April 30, 2015. The CHVI is a Canadian initiative designed to support global HIV vaccine research and development efforts.
February 23, 2015
Q&A: Dr. Mark Brockman of Simon Fraser University talks about his work on “Barriers to engaging young people in HIV vaccine trials in a priority setting”
In 2012, researcher Mark Brockman was among five Canadian principal investigators to receive funding through the Canadian HIV Vaccine Research Initiative (CHVI) for work in HIV vaccine discovery. His project on "Barriers to Engaging Young People in HIV Vaccine Trials in a Priority Setting" is exploring the social/behavioural, clinical and biomedical factors that increase the risk of HIV infection among adolescents and young adults and assessing challenges that prevent them from participating in trials. Brockman's team, based at Simon Fraser University in British Columbia, is collaborating with researchers at the University of Witswatersrand in Johannesburg and the University of KwaZulu-Natal in Durban. The team is studying 400 HIV-negative South Africans aged 16 to 24 in Soweto, near Johannesburg, and in Durban, South Africa — two areas with particularly high rates of HIV in this age group. Dr. Brockman explains the premise behind the study in this Q&A.
December 1, 2014
World AIDS Day Profile: Dr. Mario Ostrowski, principal investigator nof one of five Canadian HIV Vaccine Initiative (CHVI) large team grants in HIV vaccine research
Basic science is helping to inform new discoveries in HIV vaccine research. A Canadian research team is conducting studies to better understand how the immune system responds to HIV.
October 27, 2014
International conference in Cape Town attracts world-class research from Canada
A robust contingent of Canadian researchers will present their work this week at the HIV Research for Prevention (HIV R4P) Conference in Cape Town, South Africa.
June 11, 2014
Canadian meeting of vaccine experts shows importance of innovation and collaboration
Adopting existing innovative practices and forming broader collaborations may be needed to accelerate HIV vaccine discovery, according to experts who recently met to discuss ways to overcome barriers in HIV vaccine development.
March 28, 2014
With 2.3 million new cases of HIV every year globally, including 50,000 in the U.S. alone, internationally renowned vaccine expert José Esparza says the need for an HIV vaccine is imperative to complement other preventive interventions and bring HIV/AIDS under control.
March 7, 2014
Canadian researcher Peter A. Newman’s current research is examining clinical trial comprehension levels of men who have sex with men (MSM) and sex worker communities in Mumbai and Chennai, India. Preliminary results show there is “widespread misunderstanding and lack of acceptance” of placebo and random assignment.
October 7, 2013
International conference in Barcelona attracts world-class research from Canada
Canadian researchers will deliver some 24 presentations in Barcelona, Spain this week during AIDS Vaccine 2013 – the largest and most diverse international conference of researchers, advocates, clinicians, private sector partners and public health experts working collaboratively to advance HIV vaccine discovery.
May 17, 2013
May 18 is HIV Vaccine Awareness Day
HIV vaccine development is gaining momentum due in part to the identification of broadly neutralizing antibodies that could stop the virus from entering and infecting healthy cells, and from the results of the RV 144 HIV vaccine trial which showed over 30 per cent vaccine efficacy. These recent discoveries have renewed interest in the development of preventative vaccines for HIV.
But moving vaccines from the lab to the clinic isn't easy. Getting potential vaccines to the clinical stages and the important role of industry in this process was the subject of the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office's (ACO) annual meeting, held last month in Vancouver, B.C.
November 30, 2012
World AIDS Day, Dec. 1 2012, ushers in a renewed optimism that a safe, effective and accessible HIV vaccine is within reach, fueled by recent scientific breakthroughs and major global collaborations
Winnipeg—More than 30 years after the AIDS epidemic began researchers are still looking for a vaccine to stop the virus that has killed approximately 30 million people worldwide. Canada is playing an important role through active global collaborations necessary to succeed in HIV vaccine development. A recent analysis through the Canadian HIV Vaccine Initiative (CHVI) Alliance Coordinating Office (ACO) shows that the majority of HIV vaccine research in Canada published between 2007 and 2012 was collaborative in nature, involving either multiple Canadian institutions or researchers worldwide. Canadian researchers appeared as first and/or last author(s) on 72% of collaborative research articles, indicating the significance of their contributions.
November 1, 2012
Winnipeg—Canada’s scientists are making an impact in the global search to find an HIV vaccine, and that’s good news for the 81 per cent of Canadians who think HIV-vaccine development should be a priority.
A recent Probe Research survey found that of the 1,500 Canadians surveyed, 19 per cent said HIV-vaccine development should be a “top priority” for Canada to engage in on the international stage. Another 62 per cent said Canada’s contribution should at least be a “major priority”.
September 5, 2012
Global collaborations and strengths in basic science revealed in new White Paper
An analysis of HIV vaccine research over the past five years (2007-2012) shows that Canada is first per capita in the number of articles published when compared to other leading nations involved in HIV-vaccine research (i.e., United States, United Kingdom, France and South Africa). What’s more, Canada ranks fourth globally in the total number of scholarly articles published on HIV vaccine-related research.
Fall 2012, 2nd Issue
Health Canada's CHVI Regulatory Capacity Building Newsletter
The International Collaboration Unit of the Biologics and Genetic Therapies Directorate’s (BGTD) Office of Policy and International Collaboration (OPIC) is proud to present the second edition of their Canadian HIV Vaccine Initiative (CHVI) Regulatory Capacity Building newsletter. Download PDF
December 4, 2012
Researchers working together to optimize Canada’s contribution to an HIV prevention vaccine
The ACO was pleased to participate in the 10th biannual Canadian Immunization Conference (CIC) in December 2012. ACO Director Dr. Greg Hammond delivered a presentation on Progress and Prospects for HIV Immunization. You can see a pre-conference write-up, entitled “Researchers working together to optimize Canada’s contribution to an HIV prevention vaccine”, in the CIC’s Info-Vaccine.
December 1, 2011
Minister of Health recognizes the launch of Aboriginal AIDS Awareness Week 2011 and World AIDS Day
In recognition of both Aboriginal AIDS Awareness Week and World AIDS Day in Canada, the Honourable Leona Aglukkaq, Minister of Health, highlighted ongoing efforts against HIV and AIDS. Please click on the following link to view the complete release in English and French. For a factsheet on Canada's support for innovative HIV Vaccine Research please click here.